KalVista

A chessboard with blocks that read MA
Pharma

Italian pharma Angelini scoops up Catalyst in $4.1B deal

Italy’s Angelini Pharma will acquire Florida-based rare disease specialist Catalyst and its potential blockbuster Firdapse for $4.1 billion.
Kevin Dunleavy May 7, 2026 12:00pm
merger MA unit combine consolidate deal

Chiesi grows rare disease ambitions with $1.9B KalVista buyout

Apr 29, 2026 10:01am
FDA

KalVista secures rare disease approval following FDA delay

Jul 7, 2025 10:14am
FDA stop sign
Favicon Fierce Biotech

FDA's 'heavy workload' blamed for delaying KalVista's PDUFA date

Jun 16, 2025 4:33am